抗血管内皮生长因子靶向药物联合免疫疗法治疗乳腺癌的研究进展  

Advances in anti-VEGF-targeted drugs combined with immunotherapy in treatment of breast cancer

作　　者：鲜童丞 张雪琳 别俊[3] 罗义 XIAN Tongcheng;ZHANG Xuelin;BIE Jun;LUO Yi(Department of General Surgery,Emeishan People's Hospital,Leshan 614200,China;Department of Thyroid and Breast Surgery,the Nanchong City Central Hospital Affiliated to North Sichuan Medical College,Nanchong 637000,China;Department of Oncology,the Nanchong City Central Hospital Affiliated to North Sichuan Medical College,Nanchong 637000,China)

机构地区：[1]峨眉山市人民医院普通外科,四川乐山614200 [2]川北医学院附属南充市中心医院甲状腺乳腺外科,四川南充637000 [3]川北医学院附属南充市中心医院肿瘤科,四川南充637000

出　　处：《现代药物与临床》2024年第10期2711-2716,共6页Drugs & Clinic

基　　金：四川省科技计划项目(2023YFS0473)。

摘　　要：乳腺癌作为女性第一常见的恶性肿瘤,严重影响女性患者的生存质量。血管内皮生长因子(VEGF)已被确定为诱导肿瘤血管生成的关键因子,目前已有研究较多的用于乳腺癌治疗的抗VEGF靶向药物。另一方面,免疫疗法的出现是恶性肿瘤治疗的重大突破。抗新生血管形成药物与免疫疗法在针对乳腺癌的治疗方案中不失为一种合理的选择。总结了抗VEGF靶向药物联合免疫检查点抑制剂、肿瘤疫苗、治疗性抗体在乳腺癌治疗中的研究进展。Breast cancer,as the first common malignant tumor in women,seriously affects the quality of life of female patients.Vascular endothelial growth factor(VEGF)has been identified as the key factor to induce tumor angiogenesis.At present,there are many anti-VEGF-targeted drugs for the treatment of breast cancer.On the other hand,the emergence of immunotherapy is a major breakthrough in the treatment of malignant tumors.Anti-angiogenesis drugs and immunotherapy are a reasonable choice in treatment of breast cancer.This article summarized the research progress of anti-VEGF-targeted drugs combined with immune checkpoint inhibitors,tumor vaccines,therapeutic antibodies in the treatment of breast cancer.

关 键 词：抗血管内皮生长因子靶向药物 免疫检查点抑制剂 肿瘤疫苗 治疗性抗体 乳腺癌 血管内皮生长因子 

分 类 号：R979.1[医药卫生—药品]